BioXcel Therapeutics, Inc.
BTAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $1 | $0 | $0 |
| % Growth | 64.2% | 268% | – | – |
| Cost of Goods Sold | $2 | $1 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 5.4% | 8.7% | 94.7% | – |
| R&D Expenses | $30 | $84 | $91 | $52 |
| G&A Expenses | $33 | $64 | $56 | $0 |
| SG&A Expenses | $34 | $83 | $69 | $54 |
| Sales & Mktg Exp. | $1 | $20 | $13 | $0 |
| Other Operating Expenses | $2 | $4 | $0 | $0 |
| Operating Expenses | $67 | $172 | $160 | $106 |
| Operating Income | -$67 | -$172 | -$160 | -$106 |
| % Margin | -2,967.6% | -12,448% | -42,572% | – |
| Other Income/Exp. Net | $8 | -$7 | -$6 | -$1 |
| Pre-Tax Income | -$60 | -$179 | -$166 | -$107 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$60 | -$179 | -$166 | -$107 |
| % Margin | -2,630.1% | -12,974.9% | -44,201.9% | – |
| EPS | -23.51 | -98.35 | -94.67 | -64.87 |
| % Growth | 76.1% | -3.9% | -45.9% | – |
| EPS Diluted | -23.51 | -98.35 | -94.67 | -64.87 |
| Weighted Avg Shares Out | 3 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 3 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $6 | $3 | $0 |
| Interest Expense | $15 | $13 | $8 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$44 | -$165 | -$157 | -$107 |
| % Margin | -1,948.9% | -11,987% | -41,924.5% | – |